Compare Twist Bioscience Corp (TWST) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Western Union Co — how do they compare? Twist Bioscience Corp trades at $125.52 (market cap $8.42B), while Western Union Co trades at $6.95 (market cap $2.18B). The key difference: Twist Bioscience Corp is far larger — about 3.9× Western Union Co's market cap, and Western Union Co pays a 13.43% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TWST | WU | |
|---|---|---|
Market Cap | $8.42B | $2.18B |
Sector | Health | Technology |
52-Week High | $153.10 | $10.28 |
52-Week Low | $24.16 | $6.36 |
Enterprise Value | $8.35B | $2.09B |
Dividend Yield | — | 13.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Western Union (WU) trades at $7.00, down 2.51% on the day, reflecting a bearish technical trend and mixed earnings performance with recent quarterly misses. Valuation metrics appear attractive with a P/E of 5.65 and P/S of 0.55, but revenue has declined from $4.5B in 2022 to $4.05B in 2025. The company is pursuing a $200 million cost-saving plan by 2027 and expanding its retail footprint through partnerships like Total Wireless, while its pending acquisition of Intermex faces regulatory scrutiny.
The outlook is cautious due to declining revenue, integration risks from the Intermex deal, and a high dividend yield that some analysts view as unsustainable. Near-term catalysts include regulatory approvals for the acquisition and execution of cost-cutting initiatives, but competitive pressures and margin compression pose significant risks to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
